{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:23:39Z","timestamp":1789035819279,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.clinthera.2010.09.001","type":"journal-article","created":{"date-parts":[[2010,12,29]],"date-time":"2010-12-29T09:15:21Z","timestamp":1293614121000},"page":"1813-1821","source":"Crossref","is-referenced-by-count":20,"title":["Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers"],"prefix":"10.1016","volume":"32","author":[{"given":"Armel","family":"Stockis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Sargentini-Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Otoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Wray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.09.001_bib1","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2010.09.001_bib2","series-title":"The Treatment of Epilepsy","first-page":"559","article-title":"Levetiracetam","author":"French","year":"2009"},{"key":"10.1016\/j.clinthera.2010.09.001_bib3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2010.09.001_bib4","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.clinthera.2006.05.004","article-title":"Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects","volume":"28","author":"Ramael","year":"2006","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2010.09.001_bib5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.eplepsyres.2009.02.001","article-title":"Pharmacokinetics of levetiracetam XR 500mg tablets","volume":"84","author":"Rouits","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.clinthera.2010.09.001_bib6","first-page":"1278","article-title":"A new technique for segmental jejunal perfusion in man","volume":"84","author":"Knutson","year":"1989","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.clinthera.2010.09.001_bib7","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1023\/A:1011981317451","article-title":"Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats","volume":"15","author":"Chiou","year":"1998","journal-title":"Pharm Res."},{"key":"10.1016\/j.clinthera.2010.09.001_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/A:1007552927404","article-title":"Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans","volume":"17","author":"Chiou","year":"2000","journal-title":"Pharm Res."},{"key":"10.1016\/j.clinthera.2010.09.001_bib9","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1023\/A:1016169202830","article-title":"Comparison of oral absorption and bioavailability of drugs between monkey and human","volume":"19","author":"Chiou","year":"2002","journal-title":"Pharm Res."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2010.09.001_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1359-6446(01)00150-7","article-title":"Effect of diverse datasets on the predictive capability of ADME models in drug discovery","volume":"6","author":"Grass","year":"2001","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.clinthera.2010.09.001_bib11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1461-5347(00)00311-4","article-title":"Development of a new engineering-based capsule for human drug absorption studies","volume":"3","author":"Wilding","year":"2000","journal-title":"Pharm Sci Technol Today"},{"key":"10.1016\/j.clinthera.2010.09.001_bib12","series-title":"Modified-Release Drug Delivery Technology","first-page":"273","article-title":"The Enterion capsule","author":"Prior","year":"2003"},{"key":"10.1016\/j.clinthera.2010.09.001_bib13","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/0091270009333488","article-title":"An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat","volume":"49","author":"Connor","year":"2009","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.09.001_bib14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/0091270003252508","article-title":"Pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme\/neutral endopeptidase inhibitor, M100240, in healthy volunteers","volume":"43","author":"Martin","year":"2003","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.09.001_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0378-5173(03)00164-9","article-title":"Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules","volume":"257","author":"Oo","year":"2003","journal-title":"Int J Pharm."},{"key":"10.1016\/j.clinthera.2010.09.001_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0091270006293767","article-title":"Systemic availability of the active metabolite hydroxy-fasudil after administration of fasudil to different sites of the human gastrointestinal tract","volume":"47","author":"Hinderling","year":"2007","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.09.001_bib17","series-title":"Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland","article-title":"World Medical Association Declaration of Helsinki \u2014 Ethical Principles for Medical Research Involving Human Subjects","year":"2000"},{"key":"10.1016\/j.clinthera.2010.09.001_bib19","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1023\/A:1015855829864","article-title":"Correlation of the gastric emptying of nondisintegrating tablets with gastrointestinal motility","volume":"8","author":"Coupe","year":"1991","journal-title":"Pharm Res."},{"key":"10.1016\/j.clinthera.2010.09.001_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0278-6915(00)00136-8","article-title":"Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats","volume":"39","author":"DeSesso","year":"2001","journal-title":"Food Chem Toxicol."},{"key":"10.1016\/j.clinthera.2010.09.001_bib21","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0022-3565(24)37149-6","article-title":"Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism","volume":"283","author":"Paine","year":"1997","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.clinthera.2010.09.001_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0928-0987(00)00178-0","article-title":"Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine","volume":"12","author":"Suzuki","year":"2000","journal-title":"Eur J Pharm Sci."},{"key":"10.1016\/j.clinthera.2010.09.001_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00418-002-0479-y","article-title":"Expression of the peptide transporter hPepT1 in human colon: A potential route for colonic protein nitrogen and drug absorption","volume":"119","author":"Ford","year":"2003","journal-title":"Histochem Cell Biol."},{"key":"10.1016\/j.clinthera.2010.09.001_bib24","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1023\/A:1026183200740","article-title":"P-glycoprotein increases from proximal to distal regions of human small intestine","volume":"20","author":"Mouly","year":"2003","journal-title":"Pharm Res."},{"key":"10.1016\/j.clinthera.2010.09.001_bib25","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2362.2003.01154.x","article-title":"Variable expression of CYP and Pgp genes in the human small intestine","volume":"33","author":"Lindell","year":"2003","journal-title":"Eur J Clin Invest."},{"key":"10.1016\/j.clinthera.2010.09.001_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/1389200043489144","article-title":"Intestinal drug transporters: In vivo function and clinical importance","volume":"5","author":"Kunta","year":"2004","journal-title":"Curr Drug Metab."},{"key":"10.1016\/j.clinthera.2010.09.001_bib27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1021\/mp800261a","article-title":"Toward an increased understanding of the barriers to colonic drug absorption in humans: Implications for early controlled release candidate assessment","volume":"6","author":"Tannergren","year":"2009","journal-title":"Mol Pharm."},{"key":"10.1016\/j.clinthera.2010.09.001_bib28","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/gut.27.8.886","article-title":"Transit of pharmaceutical dosage forms through the small intestine","volume":"27","author":"Davis","year":"1986","journal-title":"Gut."},{"key":"10.1016\/j.clinthera.2010.09.001_bib29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0168-3659(93)90040-C","article-title":"Colonic transit of different sized tablets in healthy subjects","volume":"23","author":"Adkin","year":"1993","journal-title":"J Control Release"},{"key":"10.1016\/j.clinthera.2010.09.001_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(89)90082-3","article-title":"Gastric emptying and small and large bowel transit of non disintegrating tablets in fasted subjects","volume":"52","author":"Khosla","year":"1989","journal-title":"Int J Pharm."},{"key":"10.1016\/j.clinthera.2010.09.001_bib31","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.2042-7158.1985.tb04992.x","article-title":"Drug delivery to the proximal colon","volume":"37","author":"Hardy","year":"1985","journal-title":"J Pharm Pharmacol."},{"key":"10.1016\/j.clinthera.2010.09.001_bib32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.1987.tb00620.x","article-title":"Gastrointestinal transit of an enteric-coated delayed release 5-aminosalicylic acid tablet","volume":"1","author":"Hardy","year":"1987","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2010.09.001_bib33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1023\/A:1015849700421","article-title":"Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects","volume":"8","author":"Coupe","year":"1991","journal-title":"Pharm Res."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810003103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810003103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T05:11:22Z","timestamp":1740805882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810003103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0149291810003103"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.09.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}